Officials at the FDA, which had approved the studies, said their focus in reviewing the findings of the three studies was on hirudin because it was the experimental drug being compared with the standard one, heparin, and that they approved resumption of the hirudin trials because they did not want to inhibit research progress of a potentially important drug.
